Skip to main content

Table 1 Baseline Characteristics.

From: The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury

 

High dose XY2405

Medium dose XY2405

Low dose XY2405

All doses XY2405 combined

Placebo

Patients randomised: n

57

56

58

171

57

Age:

     

   mean (SD)

35.9 (14.0)

37.6 (14.3)

35.5 (13.8)

36.3 (14.0)

36.4 (14.3)

   median (min -- max)

33 (19 -- 65)

37 (18 -- 64)

32 (17 -- 61)

34 (17 -- 65)

34 (17 -- 64)

   16 -- 39 (%)

36 (63.2)

32 (57.1)

35 (60.3)

103 (60.2)

35 (61.4)

   40 -- 49 (%)

8 (14.0)

11 (19.6)

9 (15.5)

28 (16.4)

8 (14.0)

   50 + (%)

13 (22.8)

13 (23.2)

14 (24.1)

40 (23.4)

14 (24.6)

Gender: n (%)

     

   male

51 (89.5)

50 (89.3)

52 (89.7)

153 (89.5)

50 (87.7)

Time since injury:

     

   mean (SD)

5.5 (1.7)

5.7 (1.9)

5.8 (1.8)***

5.7 (1.8)

5.9 (1.6)

   median (min -- max)

5.8 (1.4 -- 8.0)

5.8 (2.1 -- 10.8)*

5.8 (1.8 -- 8.6)*

5.8 (1.4 -- 10.8)*

6.2 (2.3 -- 8.0)

   ≤ 1 hr (%)

0

0

0

0

0

   > 1hr - ≤ 3 hrs (%)

4 (7.0)

3 (5.4)

5 (8.6)

12 (7.0)

4 (7.0)

   > 3hrs - ≤ 8 hrs (%)

53 (93.0)

52 (92.9)

50 (86.2)

155 (90.6)

53 (93.0)

   > 8 hrs (%)

0

1 (1.8)

2 (3.4)

3 (1.8)

0

Glasgow Coma Score:

     

   mean (SD)

7.4 (3.0)

7.7 (3.4)

7.6 (2.9)

7.6 (3.1)

7.5 (3.0)

   median (min-max)

7 (3 -- 14)**

7 (3 -- 15)**

7 (3 -- 12)

7 (3 -- 15)**

8 (3 -- 12)

   3 -- 5 (%)

17 (29.8)

15 (26.8)

17 (29.3)

49 (28.7)

18 (31.6)

   6 -- 8 (%)

18 (31.6)

19 (33.9)

17 (29.3)

54 (31.6)

17 (29.8)

   9 -- 12 (%)

21 (36.8)

21 (37.5)

24 (41.4)

66 (38.6)

22 (38.6)

   >12 (%)

1 (1.8)

1 (1.8)

0

2 (1.2)

0

Glasgow Coma Motor Sub-score: n

     

   mean (SD)

3.8 (1.5)

3.9 (1.8)

4.1 (1.5)***

3.9 (1.6)

4.0 (1.7)

   median (min-max)

4 (1 -- 6)

5 (1 -- 6)

5 (1 -- 6)

5 (1 -- 6)

5 (1 -- 6)

Pupil reactivity to light: n (%)

     

Not testable (%)

0

0

0

0

0

Neither (%)

11 (19.3)

6 (10.7)

4 (6.9)

21 (12.3)

6 (10.5)

Only one reactive (%)

3 (5.3)

8 (14.3)

11 (19.0)

22 (12.9)

7 (12.3)

Both reactive (%)

43 (75.4)

42 (75.0)

43 (74.1)

128 (74.9)

44 (77.2)

Body Mass Index:

     

   mean (SD)

24.5 (4.0)

24.0 (2.8)

24.0 (3.1)***

24.2 (3.3)

24.9 (2.9)

   median (min-max)

24.2 (17.3 -- 39.4)

24.2 (18.1 -- 31.1)

23.4 (17.3-33.2)

23.9 (17.3 -- 39.4)

24.4 (19.7-34.6)

Temperature:

     

   mean (SD)

36.7 (0.8)#

36.6 (0.7)#

36.6 (0.8)#

36.6 (0.8)#

36.6 (0.9)#

   median (min-max)

36.9 (34.0 -- 38.9)

36.7 (33.7 -- 37.8)

36.8 (33.7 -- 38.3)

36.8 (33.7 -- 38.9)

36.8 (33.5 -- 39.4)

Systolic Blood Pressure:

     

   mean (SD)

132.6 (26.7)

128.0 (21.4)

130.4 (20.6)***

130.3 (23.0)

124.7 (22.7)

   median (min-max)

130.0 (98.0-212.0)

130.0 (91.0-200.0)

129.0 (93.0-190.0)

130.0 (91.0-212.0)

125.0 (60.0-177.0)

  1. * Three individuals had their first injection after 8 hours
  2. ** Two individuals had Glasgow coma scores >12 but fulfilled all other eligibility criteria. As per protocol (6.5.2) a waiver was granted to allow these individuals to be randomised.
  3. *** 1 missing value for low dose
  4. # 3 missing values for high dose, 2 missing values for medium dose, 1 missing value for low dose, 1 missing value for placebo